{"editorial":{"content_id":"7cfd99fb-83c1-43c3-b87f-1f3a341c3a67","slug":"cimed-top-of-mind-20261109-78f157","content_type":"news","title":"Cimed连续第四年获非专利药Top of Mind奖，销量增速超市场20%","summary":"巴西制药公司Cimed连续第四年获得《圣保罗页报》非专利药类Top of Mind奖，同期在非专利药销量上领先，增速比市场高20%。","body":"巴西制药公司Cimed连续第四年获得《圣保罗页报》（Folha de S. Paulo）颁发的非专利药（genéricos）类别Top of Mind奖，该奖项表彰消费者最记忆深刻的品牌。获奖之际，Cimed在非专利药类别的销量（单位数）上位居领先，增速比市场高出20%。\n\n公司首席执行官若昂·阿迪贝·马克斯（João Adibe Marques）表示：“如今巴西每售出100盒非专利药，就有17盒来自Cimed。”\n\n据该实验室介绍，这一地位源于分销扩张、竞争力与贴近消费者相结合的战略。公司在33种分子药物上领先，分销网络覆盖超过9万个销售点（PDV）。\n\n马克斯表示，品牌认知与规模的结合反映了公司的定位：“近50年来，我们打造了一家由巴西人创办、为巴西人服务的巴西企业，成为全国销量第三大制药公司。我们的承诺始终是推动医疗和药品的普及。”\n\nCimed预计，到2030年非专利药将占制药市场的45%。推动这一扩张的主要动力之一是Farmácia Popular项目，其药品组合中85%为非专利药。据Close-Up数据，该项目截至8月交易额达117.5亿雷亚尔，同比增长28.7%；销量增长10.3%，达7.952亿单位。目前约2.7万家药房获准参与该项目，覆盖巴西89%的城市。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["企业动态","行业趋势","br-health"],"content_level":"编辑整理","event_type":"公司动态","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-09T17:03:16.654Z","display_date":"2026-11-09","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/cimed-conquista-top-of-mind-em-genericos-pelo-4o-ano-seguido/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/cimed-top-of-mind-20261109-78f157","api_url":"https://chinabrazilinsight.com/api/public/content/cimed-top-of-mind-20261109-78f157","markdown_url":"https://chinabrazilinsight.com/api/public/content/cimed-top-of-mind-20261109-78f157?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/cimed-top-of-mind-20261109-78f157?view=json","last_updated":"2026-11-09T17:03:42.892Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}